Evidence map›Paper›PMID 36771145›Full record

ArticleMolecules (Basel, Switzerland)2023

Amyloid-like RIP1/RIP3 RHIM Fragments' Characterization and Application as a Drug Depot.

Maytham Ismail, Mathumai Kanapathipillai

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Novel Ultrasound-Responsive Amyloid Formulation.Pharmaceuticals (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Maytham IsmailDepartment of Mechanical Engineering, University of Michigan-Dearborn, Dearborn, MI 48128, USA.
Mathumai KanapathipillaiDepartment of Mechanical Engineering, University of Michigan-Dearborn, Dearborn, MI 48128, USA.
University of Michigan–Dearborn · US

Funding

Mechano sensitive peptide aggregates for targeted therapyR15GM135766 · NIGMS · UNIVERSITY OF MICHIGAN AT DEARBORN · PI KANAPATHIPILLAI, MATHUMAI · 2020 to 2020
$443k
NIGMS NIH HHS R15 GM135766
6 · The paper itself

Abstract

Amyloid aggregates play a major role in diseases as well as in normal physiological function. Receptor-interacting protein kinases 1 and 3 (RIP1/RIP3) aggregates complexes in cellular necroptosis is one example of protein aggregation in normal cellular function. Although recently there have been several studies on full kinase proteins aggregation, the aggregation potential of small peptide sequences of RIP1/RIP3, the physicochemical properties, and the potential in biomedical applications have not been explored. Hence, in this paper, we study the aggregation propensity of peptides consisting of four and twelve amino acid sequences in the RHIM region of RIP1/RIP3 proteins that are known to drive the beta-sheet formation and the subsequent aggregation. The aggregation kinetics, physicochemical characterization, mechanosensitive properties, cellular effects, and potential as a cancer drug depot have been investigated. The results show that the number and concentration of amino acids play a role in amyloid-like aggregates' properties. Further, the aggregates when formulated with cisplatin-induced significant lung cancer cell toxicity compared to an equal amount of cisplatin with and without ultrasound. The study would serve as a platform for further investigation on RIP1/RIP3 peptide and protein aggregates, their role in multiple cellular functions and diseases, and their potential as drug depots.

Indexed as

CisplatinProtein KinasesAmyloidAmyloidogenic ProteinsApoptosisHumansNecrosisAmyloidAmyloidogenic ProteinsCisplatinProtein KinasesaggregationAmyloidRIP1RIP3

Identifiers

PMID36771145
PMCPMC9918910
OpenAlexW4319159405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.